Cantargia share offering prior to planned listing on Nasdaq First North in Stockholm oversubscribed

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE USA, AUSTRALIA, HONG KONG, JAPAN, CANADA, SINGAPORE, SOUTH AFRICA OR NEW ZEALAND OR IN ANY OTHER JURISDICTION WHERE DISTRIBUTION OF THIS PRESS RELEASE WOULD BE ILLEGAL.

The subscription period for the offering of units of Cantargia AB (“Cantargia”), prior to the planned listing of the company on Nasdaq First North in Stockholm, ended on 12 February 2015. Subscriptions of approximately SEK 60 million were received (excluding guaranteed subscriptions), corresponding to 136 percent, including subscription undertakings. Under the offering, 5 800 000 new shares and 4 350 000 option rights of series TO 3 and 2 900 000 option rights of series TO 4 will be issued. Cantargia will receive about 700 new shareholders. Contract notes are scheduled to be dispatched today, 17 February 2015.

Göran Forsberg, CEO, comments:
“I would like to thank all those who have subscribed for the shares and option rights under the offering and welcome new shareholders to Cantargia. Thanks to the new capital that has been raised we will continue to operate as planned and initiate resource-intensive activities, including toxicological studies, process development and GMP manufacturing.”

Planned listing on Nasdaq First North in Stockholm
Cantargia has applied for the company’s shares and option rights to be listed on Nasdaq First North in Stockholm. Subject to approval from the marketplace, the first day of trading on Nasdaq First North in Stockholm is expected to be 17 March 2015.

Subscription and allocation
Subscriptions of approximately SEK 60 million were received, including subscription undertakings, resulting in the issuance of 5 800 000 new shares, 4 350 000 option rights of series TO 3 and 2 900 000 option rights of series TO 4. Cantargia will thereby raise around SEK 44,1 million before issue costs, which are estimated at approximately SEK 2 million. The allocation has been made in accordance with the principles described in the prospectus. There will be no allotment to guarantee subscribers.

Number of shares and share capital
When the issue has been registered with the Swedish Companies Registration Office the total number of shares in Cantargia will be 13 394 874. Upon registration the share capital will be SEK 1 071 589,92. In addition, there are 4 350 000 outstanding option rights of series TO 3 and 2 900 000 outstanding option rights of series TO 4. It should be noted that there are also outstanding option rights of series TO 1 and series TO 2, which were not issued through this offering.

Summary of terms and conditions for the option rights
One (1) option right entitles the holder to subscribe for one (1) new share. The exercise price for option rights of series TO 3 and TO 4 is SEK 7.60 per option right. Option rights of series TO 3 for the subscription of shares will be exercisable during the period 23 March – 13 April 2016. The last day of trading in option rights of series TO 3 is expected to be 11 April 2016. Option rights of series TO 4 for the subscription of shares will be exercisable during the period 27 September – 18 October 2016. The last day of trading in option rights of series TO 4 is expected to be 14 October 2016.

Financial adviser and Certified Adviser
Sedermera Fondkommission is the company’s financial adviser and Certified Adviser in connection with the offering and planned listing on Nasdaq First North in Stockholm.

For questions concerning the share offering, please contact
Sedermera Fondkommission
Telephone: +46 (0)431-47 17 00
E-mail: info@sedermera.se

For further information, please contact
Göran Forsberg, CEO
Telephone: +46 (0)46-275 62 60
E-mail: goran.forsberg@cantargia.com

Cantargia AB (reg.no. 556791-6019) is a biotech company that is developing an antibody-based cancer treatment, which attacks cancer stem cells as well as mature cancer cells. The original discovery by the research team behind Cantargia was the overexpression of a specific target molecule, IL1RAP, in cancer stem cells in patients with leukaemia that is not found in normal stem cells in the bone marrow. In preclinical studies (in vitro and in vivo) the antibody, targeted at IL1RAP, has been shown to have two potential mechanisms of action, which are complementary. The company has selected a product candidate for future studies in humans. Preclinical trials with Cantargia’s antibodies have shown a potent antileukaemic effect. Parallel studies have shown an even higher expression of IL1RAP in certain solid tumours. In 2015 Cantargia will be carrying out the studies required for authorisation of clinical trials.

---